Does Neuriva Work? The 100 mg Problem and the Settlement That Was Thrown Out

Does Neuriva Work? The 100 mg Problem and the Settlement That Was Thrown Out

A single company-funded trial on the finished Neuriva formula found that 138 adults improved on some computerized cognitive tasks after 42 days but showed no difference on others, including the participants' own report of whether their everyday memory got better. The 2021 class-action settlement that would have restricted how Neuriva is marketed was vacated by the Eleventh Circuit on April 12, 2023, so no court order limits the company's claims today. Below is what the capsule actually contains, what the trial actually measured, and what the legal record actually says.

Key Takeaways

• One trial on the actual product exists. It is company-funded, 42 days long, and mixed: some outcomes improved, some did not.
• The phosphatidylserine dose is 100 mg. Most older trials reporting memory benefits used 300 mg daily.
• "Clinically tested" is not "clinically proven." Tested describes an event. Proven describes a result.
• The class-action settlement was thrown out on appeal. No payout was made. No court order restricts Neuriva's marketing.
• Neuriva is legal and safe for most people. The question is whether the evidence justifies the price, and the honest answer is: maybe, weakly, for some measures, after six weeks.

What Is Actually in the Capsule

Sources: Neuriva Original product listing, Neuriva Plus product page, Pharmacy Times.

This is a two-ingredient product wearing a five-benefit label (seven across the broader Neuriva line). Neuriva Original is coffee cherry extract plus phosphatidylserine. Neuriva Plus doubles the coffee cherry extract and adds a B-vitamin stack (B6, B12, folic acid). Both are decaffeinated. The phosphatidylserine is plant-sourced, from soy, which matters if you have a soy allergy and matters scientifically because most of the older, positive phosphatidylserine studies used bovine-cortex-derived PS, which has a different fatty acid profile.

The One Trial on the Actual Product, Read Properly

This is the section that most reviews skip or oversimplify.

In 2023, Neurology and Therapy published a randomized, double-blind, placebo-controlled trial on the finished Neuriva formulation. The trial enrolled 138 healthy adults aged 40 to 65 with self-perceived memory problems and ran for 42 days. It was funded by Reckitt, the company that makes Neuriva.

What reached statistical significance at day 42:

• Numeric working memory accuracy on the COMPASS battery (p ≤ 0.024)
• Reaction time outcomes (p ≤ 0.031)
• Overall accuracy on a picture recognition task (p = 0.035)

What did not reach significance:

• BDNF levels (brain-derived neurotrophic factor), the blood marker that Neurofactor's entire marketing story is built on
• The Everyday Memory Questionnaire (EMQ), which is the participants' own report of whether their real-world memory improved
• Go/No-Go tests, which measure impulse control and attention

The BDNF null result matters because Neurofactor is sold on the premise that it raises BDNF, and in this trial it did not separate from placebo over 42 days. The EMQ null result matters because it means participants who took Neuriva did not report noticing a difference in their daily memory compared to placebo. The improvements showed up on computerized tasks. They did not show up in the way people experienced their own memory.

This is not a not supported by the evidence trial. It is a single, company-funded, 42-day study with mixed results. That is a long way from "clinically proven."

The 100 mg Problem

Neuriva delivers 100 mg of phosphatidylserine per capsule. That is the low end of the range studied in cognitive research.

The older trials most often cited for phosphatidylserine and memory used 100 to 300 mg daily, with the strongest results clustered at 300 mg, often from bovine-cortex-derived material. A Japanese trial in elderly subjects with mild cognitive impairment tested both 100 mg and 300 mg daily for six months and found memory improvements in both the 100 mg and 300 mg groups, with additional benefits in the 300 mg subgroup that had lower baseline cognitive scores.

The Examine.com summary of phosphatidylserine research notes that 100 mg once daily may provide some degree of benefit but that higher doses have shown stronger results in the literature.

None of this proves that 100 mg is useless. It means Neuriva chose the bottom of the studied range. If you are paying for phosphatidylserine and the research literature points to 300 mg, you should know you are getting a third of that.

What "Clinically Tested" Means, and What It Does Not

Neuriva's label says "clinically tested." Its website says the ingredients are backed by "over 15 clinical studies to support memory, focus and cognitive performance" and that the product supports "up to 7 brain health indicators."

Here is the distinction that matters. "Clinically tested" describes an event: someone ran a clinical study involving this product or its ingredients. "Clinically proven" describes a result: the evidence is strong enough to say the product works. The label says the first. The advertising lets you hear the second.

Most of those "15+ clinical studies" are studies on individual ingredients, not on this capsule at this dose in this combination. The FTC's Health Products Compliance Guidance (December 2022) states that a cognition or memory claim needs methodologically sound human clinical research on the product itself, using appropriate outcome measures, and that ingredient research must match the dose, form, and population. That is the standard. Apply it to any supplement, not just this one.

The Lawsuit, Dated Correctly

Several pages still ranking on Google say that a settled lawsuit "bars" or "prohibits" Neuriva from claiming it works. That has been wrong since April 2023. Here is what actually happened.

2020: Multiple class-action lawsuits were filed against Reckitt Benckiser LLC alleging Neuriva was falsely marketed as clinically proven to improve brain performance. Claims were brought under Florida, California, and New York consumer protection law.

February 2021: Plaintiffs in Williams v. Reckitt Benckiser LLC (S.D. Fla., 20-23564) moved for preliminary approval of a proposed settlement. The proposed deal: up to $8 million in monetary relief, with class members eligible for $32.50 with proof of purchase (up to two products) or $5 without proof (up to four products), plus injunctive relief restricting future marketing language.

March 2022: The district court granted final approval.

April 12, 2023: The Eleventh Circuit vacated the settlement. The appeals court held that none of the named plaintiffs had Article III standing to seek injunctive relief because none alleged they intended to buy Neuriva again. Without standing, the district court lacked jurisdiction to approve the settlement as structured.

August 2023: The Eleventh Circuit denied rehearing en banc. The $2.6 million attorneys' fee award was vacated along with the settlement.

Where it stands in 2026: No court-approved settlement is in force. No class payout was made under the vacated deal. No court order restricts how Neuriva is advertised. Reckitt switched from "clinically proven" to "clinically tested" as a matter of its own choice, not by court mandate. The public record ends with the August 2023 denial of rehearing. If the legal status matters to you, check for newer filings.

A settlement is not a finding of liability. The vacatur is not an exoneration. Neither side "won" or "lost" in the way most people mean those words. The procedural outcome turned on standing doctrine, not on whether the advertising was true.

Neuriva Original vs. Neuriva Plus vs. Gummies

The 2023 trial tested the commercial Neuriva formulation. It did not test the Plus variant or the gummies separately.

Neuriva Plus mostly means more Neurofactor (twice the Original's amount) plus a B-vitamin stack. The B vitamins (B6, B12, folic acid) are well-studied nutrients, but supplementing them only helps cognitive function if you are deficient. If your B12 levels are normal, extra B12 does not sharpen your memory. The gummies contain the same active ingredients in the same branded forms, though excipient profiles differ.

If your question is "which one has the most evidence behind it," the answer is the Original capsule, because that is what was tested in the one trial on the finished product.

Cost Per Month

Neuriva Original runs roughly $27 to $35 for a 30-count bottle at major U.S. retailers, depending on the store and current promotions (prices checked June 2025). Neuriva Plus typically costs a few dollars more. That puts the monthly cost somewhere between $0.90 and $1.17 per day.

You are buying two active ingredients. One (coffee cherry extract) has no long-term cognitive trials independent of the company that sells it. The other (phosphatidylserine) has a longer research history but at doses mostly higher than what this capsule delivers. That is the arithmetic. Whether it is worth it depends on how much certainty you need from a supplement.

Who Might Reasonably Try It, and Who Should Not Bother

If you are a healthy adult between 40 and 65, you want a low-risk 42-day self-experiment on a product that showed a signal on some computerized tasks in a company-funded trial, and you can afford $30 a month without it mattering, that is a legitimate personal choice. It is not proof. It is a bet on a weak signal.

If you want strong evidence before spending money, this is not it. One mixed trial funded by the manufacturer, with null results on the outcomes most people care about (their own perception of memory), does not meet that bar.

If you are on blood thinners, talk to your pharmacist first. Phosphatidylserine may interact with anticoagulant medications. If you have a soy allergy, Neuriva is off the table: the label says "CONTAINS SOY."

What the Evidence Actually Supports if Memory Is Your Goal

The interventions with the strongest, most replicated evidence for preserving cognitive function over time are not supplements. They are:

• Sleep: consistent, sufficient sleep (the research points to 7 to 9 hours for adults)
• Exercise: regular aerobic activity, even moderate walking
• Hearing and vision correction: untreated hearing loss is a leading modifiable risk factor for dementia
• Spaced retrieval practice: actively testing your memory rather than passively reviewing information
• Vitamin and mineral screening: getting your B12 and vitamin D levels checked by a doctor rather than guessing and supplementing blindly

None of these come in a capsule. All of them have decades of replication behind them. If you are spending $30 a month on a brain supplement but sleeping six hours a night, you are optimizing in the wrong order.

Conclusion

The question "does Neuriva work" does not have a clean yes or no answer. One company-funded, 42-day trial found improvements on some computerized cognitive tasks but not on others, and participants themselves did not report better everyday memory. The phosphatidylserine dose sits at the bottom of the range where research has found benefits, and the coffee cherry extract lacks independent long-term data. The class-action settlement that would have restricted Neuriva's marketing was vacated on procedural grounds, so no court order is in effect. Neuriva is a legal, generally safe supplement with a weak and incomplete evidence base. Whether that is enough depends on your personal standard of proof and what else you are doing for your brain health.

Frequently Asked Questions

Does Neuriva actually improve memory?

In the one trial on the finished product, Neuriva improved scores on some computerized memory and reaction time tasks after 42 days compared to placebo. But participants' own reports of their everyday memory (the Everyday Memory Questionnaire) did not improve relative to placebo. The answer depends on what you mean by "memory." On a lab task, there was a signal. In daily life, the people taking it did not notice a difference.

Did Neuriva lose its lawsuit, and did anyone get money?

No. Multiple class-action suits were filed in 2020 alleging false advertising. A nationwide settlement of up to $8 million was approved in 2022, but the Eleventh Circuit vacated it in April 2023 on standing grounds. No class payout was made. No court found the advertising was false. The case ended on a procedural issue, not a verdict on the science.

How long does Neuriva take to work?

The only trial on the finished product measured outcomes at day 42. It did not test shorter intervals. Neuriva's own guidance says to take one capsule daily for at least 30 days. There is no published evidence for effects before that window.

Is Neuriva Plus better than Neuriva Original?

The 2023 clinical trial tested the Original formulation, not Plus. Plus adds more coffee cherry extract and a B-vitamin stack (B6, B12, folic acid). The extra B vitamins support brain health only if you are deficient. If your levels are already normal, the difference between Original and Plus is an unknown amount of extra coffee cherry extract, which has no independent long-term cognitive trials.

Does Neuriva contain caffeine?

Negligible amounts. The coffee cherry extract in Neuriva is decaffeinated. Pharmacy Times reports less than 4 mg per dose, which is roughly what you would get from a few sips of decaf coffee. It is not a stimulant product.

Is "clinically tested" the same as "clinically proven"?

No. "Clinically tested" means a clinical study was conducted involving the product or its ingredients. It says nothing about the outcome. "Clinically proven" would mean the evidence is strong enough to confirm the product works as claimed. The FTC's 2022 Health Products Compliance Guidance requires that efficacy claims be supported by methodologically sound human research on the product itself at the marketed dose. "Tested" sidesteps that standard without technically lying.

The 100 mg Problem Does Not Apply to a 6 to 8 Hour Work Block

Neuriva is built around a daily nootropic thesis: take coffee fruit extract and phosphatidylserine every morning and expect cognitive benefits over 30 or more days. For people drawn to that category, the product is at least backed by ingredient-level research, even if the dose and the product-level evidence remain contested. That is a fair statement of where it stands.

Roon asks a narrower question. It is a zero sugar sublingual caffeine pouch (80 mg caffeine, 60 mg L-theanine, 25 mg methylliberine, 5 mg theacrine) designed for acute alertness across a 6 to 8 hour window. It makes no memory or cognitive-improvement claim, and 80 mg of caffeine is below the threshold studied in caffeine-and-memory trials. Stop at least 8 hours before bed. Subscriptions start from $9.16 per tin, or as little as $0.61 per pouch; one-time 4-tin orders are $15.00 per tin.

Different timelines, different claims. Long-term brain health belongs with a clinician. Roon is just a caffeine product for the task in front of you.

Written by Roon Team